Search

Home > OIS Podcast > Biogen’s High Hopes For Gene Therapy, Ophthalmology
Podcast: OIS Podcast
Episode:

Biogen’s High Hopes For Gene Therapy, Ophthalmology
Category: Business
Duration: 00:17:46
Publish Date: 2015-10-20 23:00:00
Description: In July, Biogen signed a potential $1 billion-plus deal with Applied Genetic Technologies Corp. The deal, which included an equity investment, centered around AGTC’s leading gene therapy programs developing treatments for rare ophthalmic conditions X -Linked Retinoschisis (XLRS) and X-linked Retinitis Pigmentosa (XLRP). In this podcast, Josh Mandel-Brehm, Director, Business Development and M&A at Bio-gen,discusses how Biogen and AGTC spoke for over a year before the deal came together. Calling the eye, “the window into the brain,” Mandel-Brehm says neurology-focused Biogen might be looking to find new partners in the future.
Total Play: 0